Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - AccuredRetained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Janux Therapeutics (JANX) Other Non-Current Assets (2021 - 2025)

Janux Therapeutics (JANX) has disclosed Other Non-Current Assets for 5 consecutive years, with $2.6 million as the latest value for Q4 2025.

  • On a quarterly basis, Other Non-Current Assets rose 219.61% to $2.6 million in Q4 2025 year-over-year; TTM through Dec 2025 was $2.6 million, a 219.61% increase, with the full-year FY2025 number at $2.6 million, up 219.61% from a year prior.
  • Other Non-Current Assets was $2.6 million for Q4 2025 at Janux Therapeutics, up from $816000.0 in the prior quarter.
  • In the past five years, Other Non-Current Assets ranged from a high of $2.8 million in Q3 2024 to a low of $140000.0 in Q3 2021.
  • A 5-year average of $1.4 million and a median of $816000.0 in 2022 define the central range for Other Non-Current Assets.
  • Peak YoY movement for Other Non-Current Assets: skyrocketed 923.57% in 2022, then tumbled 71.09% in 2025.
  • Janux Therapeutics' Other Non-Current Assets stood at $392000.0 in 2021, then surged by 108.16% to $816000.0 in 2022, then surged by 207.48% to $2.5 million in 2023, then tumbled by 67.48% to $816000.0 in 2024, then soared by 219.61% to $2.6 million in 2025.
  • Per Business Quant, the three most recent readings for JANX's Other Non-Current Assets are $2.6 million (Q4 2025), $816000.0 (Q3 2025), and $2.7 million (Q2 2025).